Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). The most prescribed peptide-based therapeutic globally.
Quick Reference
- Onset
- Days-weeks (cumulative)
- Duration
- Weekly dosing
- Intensity
- Moderate-strong
- Legal status
- Legal (US)
- Evidence level
- Research-backed
Key Compounds
Effects
The Science
Content generated via CMS — mechanism of action, pharmacology, and research summaries will appear here.
Dosage
Content generated via CMS — dosage tiers, timing recommendations, and form-specific guidance will appear here.
Forms & How to Use
Content generated via CMS — available forms (powder, capsule, tincture, etc.) and preparation guidance will appear here.
Safety
Content generated via CMS — contraindications, interactions, and safety profile information will appear here.
Health Disclaimer: This information is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before using any substance, especially if you take medications or have a medical condition.
Legal Status
An interactive legal status map will appear here. Check legality by state and country.
Trusted Vendors
Vendor listings coming soon. We vet every vendor for third-party testing, GMP compliance, and transparent sourcing.
Key Compounds
Featured In
Ozempic: A Weight Loss Miracle or Metabolic Menace?
by Dr. Mark Hyman · Apr 15, 2024
“Deep dive into semaglutide — almost bioidentical to GLP-1 with modified half-life. Potential beyond weight loss.”
AMA #45: Pros and Cons of GLP-1 Weight Loss Drugs
by Dr. Peter Attia · Dec 1, 2023
“Detailed analysis of GLP-1 agonists — efficacy, side effects, muscle loss concerns.”
Office Hours: Peptides 101 — GLP-1, Recovery, and Anti-Aging
by Dr. Mark Hyman · Mar 9, 2026
“What peptides are, how they influence metabolism and recovery. GLP-1 agonists featured prominently.”
Sources & Citations
Content generated via CMS — peer-reviewed references, clinical trials, and source links will appear here.